HIV vaccine - GlaxoSmithKline

Drug Profile

HIV vaccine - GlaxoSmithKline

Alternative Names: 732461; 732462; GSK-732462; GSK732461; SB-732461; SB-732462

Latest Information Update: 27 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 01 May 2014 GlaxoSmithKline completes a phase I follow-up trial in IV infections in Germany, France, Spain and USA (NCT01092611)
  • 08 Dec 2011 GlaxoSmithKline completes enrolment in its phase II trial for HIV infections (treatment-naive patients) in France, Germany, Spain and USA (NCT01218113)
  • 30 Nov 2010 Phase-II clinical trials in HIV infections (treatment-naive patients) in France (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top